BICX - BioCorRx Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0894
-0.0006 (-0.67%)
At close: 2:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.0900
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume251,989
Market Cap22.635M
Beta (3Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateNov 14, 2018 - Nov 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.13
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001

    ANAHEIM, CA, Oct. 09, 2018 -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder  via.

  • GlobeNewswire14 days ago

    BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida

    ANAHEIM, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2018 Annual Conference at the Orange County Convention Center in Orlando, Florida on October 6-9th. The IACP Annual Conference and Exposition is the leading law enforcement event, bringing more than 14,000 public safety professionals to learn new techniques and advance their knowledge through 200+ workshops in 12 targeted tracks, live demos, hands-on exhibits, new products and networking opportunities.

  • GlobeNewswire17 days ago

    BioCorRx Provides BICX102 Grant Update

    The National Institute on Drug Abuse has reviewed the grant submission for BICX102 as scheduled. The company received a summary statement shortly after the scientific review which indicated an impact score of 27. Yesterday, the Company received a Just-In-Time (JIT) request from NIDA.

  • GlobeNewswire24 days ago

    BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew

    ANAHEIM, CA, Sept. 25, 2018 -- via NEWMEDIAWIRE-- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and.

  • GlobeNewswire29 days ago

    BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress

    This conference will address the state of science in pain management, characterize the epidemiology of the opioid epidemic, and identify actions that can be taken to respond to this crisis. Brady Granier, CEO, President, and Director of BioCorRx, stated, “We look forward to engaging with top thought leaders, as well as state and federal officials at the National Opioid Crisis Management Congress next week. Millions of Americans are suffering from opioid use disorder and the BioCorRx® Recovery Program is an ideal solution available now for many of those suffering, as it combines medications like naltrexone with cognitive behavioral therapy (CBT) and peer recovery support.

  • GlobeNewswirelast month

    Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program

    ANAHEIM, CA, Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that actor Jeremy Miller appeared on Omaha, Nebraska’s local news channel, KETV NewsWatch ABC 7 Chronicle, on September 9, 2018, supporting the BioCorRx® Recovery Program. The I Got Sober treatment center, located in Omaha, Nebraska, utilizes the BioCorRx® Recovery Program to assist in treating their patients suffering from substance use disorder.

  • GlobeNewswire2 months ago

    BioCorRx Provides Business Update for the Second Quarter of 2018

    BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2018.  In June, BioCorRx® announced it has completed a capital raise of $1.1 million.

  • GlobeNewswire2 months ago

    BioCorRx Provides Update on BICX102

    BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a general update on BICX102, the Company’s sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The company previously announced that a grant application was submitted to the National Institutes of Health (NIH) in May for the development of BICX102. This specific grant opportunity, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3), was created as a result of the current opioid epidemic.

  • GlobeNewswire3 months ago

    Brady Grainer, CEO of BioCorRX Inc. Joins Everett Jolly on “Stock Day”

    PHOENIX, Ariz., July 24, 2018-- Uptick Newswire, today announced the return of BradyGrainer, CEO of BioCorRX Inc. to Uptick Newswire’ s Stock Day podcast with Everett Jolly. The Company is a developer ...

  • ACCESSWIRE7 months ago

    SeeThruEquity Issues Update on BioCorRx Inc. (OTCQB: BICX) and Increases Price Target to $0.44

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...

  • ACCESSWIRE8 months ago

    The Story Behind Growth: New Report Discusses Biocorrx and Repro-Med - Emerging Trends Within New Industry

    NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Biocorrx, Inc. (OTCQB: BICX) and Repro-Med Systems, Inc. (OTCQX: ...